問卷

TPIDB > Study Site

Study Site



MacKay Memorial Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • mmhcto@gmail.com
  • Alice Huang
  • 25433535-2851
  • 104Taipei CityJhong ShanNo. 92, Sec. 2, Zhongshan N. Rd., Taipei City 10449, Taiwan

篩選

List

589Cases

2007-02-01 - 2009-03-30

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2008-03-15 - 2009-03-14

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2011-10-01 - 2014-12-31

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2015-08-01 - 2022-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

-

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

2017-08-10 - 2025-01-09

Phase III

Completed
A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma
  • Condition/Disease

    Patients with unresectable, previously untreated advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).

  • Test Drug

    Injection Injection

Participate Sites
12Sites

Recruiting12Sites

2015-11-30 - 2026-05-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2025-02-01 - 2025-08-05

Phase II

Completed
A multinational, multicenter, double-blind, placebo-controlled Phase 2 study to evaluate efficacy and safety of SAR444656 in adult participants with moderate to severe atopic dermatitis
  • Condition/Disease

    moderate to severe atopic dermatitis

  • Test Drug

    tablet

Participate Sites
4Sites

Recruiting4Sites

2025-06-13 - 2030-06-30

Phase III

Active
An Open-label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants with Primary Membranous Nephropathy (PMN) [PROMINENT]
  • Condition/Disease

    Primary Membranous Nephropathy (PMN)

  • Test Drug

    powder

Participate Sites
10Sites

Recruiting10Sites

2023-06-30 - 2030-12-31

Phase III

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
7Sites

Recruiting7Sites